The new studies of this technology will incorporate influenza genes to assess their improved immunity against influenza and other diseases.
“While our initial development efforts will focus on an influenza vaccine, we will also be researching applications of this promising technology for a variety of other biodefense and disease prevention applications,” said Richter King senior vice president of research at GenVec.
GenVec has several adenovector based vaccines currently in development against a variety of diseases, including HIV, malaria, pandemic flu and foot and mouth disease.